Sun Pharma Q2 Review - Domestic Formulation, U.S. (ex-Taro) On Steady Footing: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Sun Pharmaceutical Industries Ltd. delivered yet another robust quarterly performance, with the beat on margins led by domestic formulation / emerging markets and sustained momentum in global specialty sales.
We raise our earnings estimate by 7%/3% for FY22E/FY23E, factoring in-
a continued ramp-up in the Ilumya-led specialty portfolio,
faster growth in non-Covid-19, chronic therapy sales in domestic formualtion,
superior traction in emerging markets, and
deferred research and development spending on specialty clinical trials.
We remain positive on Sun Pharma’s-
increasing portfolio offerings in the specialty segment,
market share gains in the branded generics segment, and
a healthy and steady pace of launches in U.S. generics (excluding-Taro).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.